^
Association details:
| Biomarker: | CDH1 mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) + epirubicin (Topoisomerase II inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
CDH1 mutations predict resistance to neoadjuvant taxane therapy
Published date:
12/02/2023
Excerpt:
In the EpiTax neoadjuvant trial, enrolling patients between 1997-2003, patients with primary breast cancers (T2 >4cm, T3/T4 and/or N2/N3) were randomized to epirubicin 90mg/m2/3W or paclitaxel 200mg/m²/3W monotherapy, with cross-over in case of inferior response....CDH1 mutations predicted resistance also within the subgroup of lobular cases (p=0.002)...mutations in CDH1 predicted resistance to paclitaxel and epirubicin.
